Therapeutic Use of Calcimimetics
- 1 February 2006
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 57 (1) , 349-364
Abstract
It has long been recognized that the secretion of PTH by chief cells in the parathyroid gland is regulated by extracellular ionized calcium. The molecular mechanism by which extracellular Ca2+performs this feat was deduced by the cloning of the extracellular calcium-sensing receptor (CaSR) in 1993 in the laboratories of Brown and Hebert. The CaSR is a G protein–coupled cell surface receptor that belongs to family 3 of the GPCR superfamily. The CaSR senses the extracellular ionic activity of the divalent minerals Ca2+and Mg2+and translates this information, via a complex array of cellular signaling pathways, to modify cell and tissue function. Genetic studies have demonstrated that the activity of this receptor determines the steady-state plasma calcium concentration in humans by regulating key elements in the calcium homeostatic system. CaSR agonists (calcimimetics) and antagonists (calcilytics) have been identified and have provided both current and potential therapies for a variety of disorders. Calcimimetics can effectively reduce PTH secretion in all forms of hyperparathyroidism. They are likely to become a major therapy for secondary hyperparathyroidism associated with renal failure and for treatment of certain patients with primary hyperparathyroidism. On the therapeutic horizon are calcilytics that can transiently increase PTH and may prove useful in the treatment of osteoporosis.Keywords
This publication has 111 references indexed in Scilit:
- Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2005
- Structural organization and biological relevance of oscillatory parathyroid hormone secretionPediatric Nephrology, 2005
- Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidismKidney International, 2005
- METABOLISM AND DISPOSITION OF CALCIMIMETIC AGENT CINACALCET HCL IN HUMANS AND ANIMAL MODELSDrug Metabolism and Disposition, 2004
- Calcimimetics?fooling the calcium receptorPediatric Nephrology, 2004
- N1‐Arylsulfonyl‐N2‐(1‐(1‐naphthyl)ethyl)‐1,2‐diaminocyclohexanes: A New Class of Calcilytic Agents Acting at the Calcium‐Sensing ReceptorChemBioChem, 2004
- Mitogen-Activated Protein Kinase Cascade in Human Normal and Tumoral Parathyroid CellsThe Journal of Clinical Endocrinology & Metabolism, 2002
- Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal DiseaseHypertension, 2001
- Tumor-Specific Decreased Expression of Calcium Sensing Receptor Messenger Ribonucleic Acid in Sporadic Primary HyperparathyroidismThe Journal of Clinical Endocrinology & Metabolism, 1997
- Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumorsThe Journal of Clinical Endocrinology & Metabolism, 1995